Aligos therapeutics begins dosing with stops™ molecule drug candidate, alg-010133, in first cohort of chronic hepatitis b patients in a phase 1 proof-of-concept study

The first drug candidate in aligos's chronic hepatitis b portfolio to be administered to chb patients the first drug candidate in aligos's chronic hepatitis b portfolio to be administered to chb patients
ALGS Ratings Summary
ALGS Quant Ranking